BridgeBio Reports Strong Q2 2026 Results with $243.7M Revenue and Key Pipeline Advances — BridgeBio Pharma, Inc.

Event summary

$243.7 million in total Q2 revenues, driven by $222.4 million from Attruby® net product revenue.
All three planned NDAs submitted to the FDA: BBP-418 for LGMD2I/R9 with Priority Review (PDUFA November 27, 2026), encaleret for ADH1 with Priority Review (PDUFA May 8, 2027), and oral infigratinib for achondroplasia.
$720.2 million in cash, cash equivalents, and marketable securities as of June 30, 2026, plus $1 billion preferred equity financing closed on July 1, 2026.

The big picture

BridgeBio's strong Q2 2026 results highlight its growing commercial success with Attruby®, coupled with significant progress in its pipeline. The company's strategic focus on rare diseases and its ability to secure substantial financing position it well for multiple potential approvals in the coming years. However, executing on these regulatory milestones and maintaining commercial momentum will be critical to sustaining growth.

What we're watching

Regulatory Milestones: The pace at which the FDA will review and approve BBP-418, encaleret, and oral infigratinib, given their Priority Review statuses.
Commercial Execution: Whether BridgeBio can sustain Attruby's growth while preparing for three potential launches in different disease areas.
Pipeline Expansion: How the expansion of oral encaleret and oral infigratinib franchises beyond their first indications will impact long-term revenue streams.